Xencor 公布了第四季度收益，每股收益较预期低 0.67 美元，净利润率为负值 81.94%，净资产收益率为负值 17.26%。 Xencor reported Q4 earnings, missing EPS estimate by $0.67, with 81.94% negative net margin and 17.26% negative ROE.
生物制药公司Xencor（纳斯达克股票代码：XNCR）公布了第四季度收益报告，较分析师普遍预期的每股收益0.36美元低0.67美元，净利润率为负值81.94%，股本回报率为负值17.26%。 Biopharmaceutical company Xencor (NASDAQ:XNCR) reported Q4 earnings, missing analysts' consensus estimate of $0.36 EPS by $0.67, with a negative net margin of 81.94% and a negative return on equity of 17.26%. 收入为 4470 万美元，同比增长 106.9%，创 12 个月新高至 32.59 美元。 Revenue was $44.70M, up 106.9% YoY, with a 12-month high of $32.59. 周三中午，该股下跌 3.88 美元，至 22.64 美元，市值为 $1.38B，市盈率为 -11.44，贝塔值为 0.70。 Shares traded down $3.88 to $22.64 on midday Wednesday, having a market cap of $1.38B, a P/E ratio of -11.44, and a beta of 0.70.